Prof. @ Harvard University, Broad Institute, & Wyss Institute. Understanding the natural world by building a synthetic one. Website: khalillab.github.io
Attn eVOLVER users & enthusiasts. 2 BIG developments!
1) New open-source eVOLVER wiki, which will be a hub for guides and documentation: khalil-lab.gitbook.io/evolve…
2) eVOLVER software version 2.0 is now available! Read about the new features on the forum: evolver.bio/t/evolver-wiki-s…
The plant kingdom is rich with molecules that influence human serotonin signaling. Here, we uncover how the medicinal Kanna plant constructs mesembrine, one of the few serotonin reuptake inhibitors found in nature. Excellent work by @cyhkim!
biorxiv.org/content/10.64898…
WOW!! Incredibly exciting to see this wonderful news! 18 years after we showed that BCL11A was an ideal target for HbF induction, Casgevy received FDA approval, other approaches like post-transcriptional silencing of BCL11A have shown clinical success, and now we have these results from @BeamTx! 👏👏
1/🚨WOW! Beam Therapeutics has announced positive topline results from its BEACON Phase 1/2 study aimed to evaluate ristoglogene autogetemcel (risto-cel) - formally known as $BEAM - 101, in sickle cell disease patients (SCD) with severe vaso-occlusive crises (VOCs). Not only did Beam’s BEACON trial successfully achieved its primary efficacy endpoint - freedom from severe Vaso-occlusive Crises (VOCs) for at least 12 consecutive months, the trail also met all of its primary safety endpoints and secondary endpoints - including freedom from inpatient hospitalization for severe VOCs during a period of 12 consecutive months. These outstanding results supports Beam’s planned U.S. Biologics License Application (BLA) submission to the U.S FDA for risto-cel, which is expected as early as Year-End 2026 - making it Beam’s first potential commercial product in the market.
The common thread in all of these cases is the use of ubiquitous CAG promoter (with CMV enhancer) into young children with dividing cells with higher vector doses. All CNS directed. The driver are subgenomic fragments of AAV, containing promoter alone.
endpoints.news/seven-new-tum…
Jon Clardy: 1943-2026
One of the most impactful, creative, and (quietly) irreverent practitioners of chemical biology. Transformed how we think about nature's chemicals: their structures, their role in biology. Loved him -- he had tremendous influence on my thinking.
What drives T-DNA integration? We couldn’t get a convincing answer with existing tools, so we built one!
Our new preprint introduces a synthetic biology approach to tracking T-DNA delivery and integration in plants 🌱 biorxiv.org/content/10.64898…
Fantastic Junior Group leader position at the Curie Institute in Paris!! Areas of interest include stem cells, tissue growth and morphogenesis, epigenetics, genomics, integrated physiology, metabolism, and synthetic embryo models. Please RT!
jpi-recruitment-curie-umr321…
This work led by @jennbrophy7 and her student @vivzhong97 in collaboration with my lab & student Michaela Jones published online this morning at Nature Biotechnology
nature.com/articles/s41587-0…
Helps limit engr'd microbial functions to target plants
Exciting science, amazing collab
We engineer both plants and bacteria to establish non-standard amino acids as a new molecular language for programming plant-microbe interactions. This work contributes to the growing toolkit for precision agriculture and we hope it accelerates the path to a sustainable future!
We have two faculty positions open in synthetic biology (one experimental and one computational), both very broadly defined. Deadline is Oct 31. The Dept of Bioengineering in the Knight Campus at UOregon is a great place to work. Come join us! Link below.
1/5 Telomerase has long been linked to chromosome maintenance in eukaryotes. Now, we show that telomerase-like activity is also present in bacteria, shedding new light on its ancient origins.
Excited to share that our work on DRT10 is now out in @Nature!
nature.com/articles/s41586-0…
PAM scanning, a CRISPR-based technique, maps where proteins tolerate insertions by testing function in living cells, and scales to any gene expressible in yeast. Out in JBC: 91 yeast GPCR chimeras, sites transferred to human A2A and MTNR1A receptors.
doi.org/10.1016/j.jbc.2026.1…
of course that's your contention. you're a first-year frontier bio guy. you just finished reading about CRISPR, probably watched a Doudna talk too. so now you're convinced everything is just gene editing.
that's gonna last until next month when you discover base editing, and then you're gonna be talkin' about how cutting DNA was barbaric and double-strand breaks are a legacy approach.
then you're gonna read about delivery, and suddenly everything's about lipid nanoparticles and how editing was the easy part and the whole goddamn thing is bottlenecked by getting it to the right organ.
that'll last until somebody shows you AlphaFold, and then you're gonna be in here regurgitating DeepMind, talkin' about de novo enzymes and virtual cells and how wet labs are economically obsolete.
then six months from now you'll watch one assay fail four times in a real lab, and start telling everybody the bottleneck was never ideas, it's validation.
somewhere in there you'll find a guy named Keith on Telegram, and you'll start doing reconstitution math in your head at dinner.
and by next year you're gonna be standing right here explaining to me you reversed your biological age by six years because you picked the clock that said so.
Exciting day for DNA Typewriter w/ 2 papers from the lab & SeaHub out today :)
1. Mouse lineage from E0 to E13.5
science.org/doi/10.1126/scie…
2. A fluctuation test for gastruloid heterogeneity
cell.com/cell/fulltext/S0092…
Paper #1 covered in quoted thread. More on paper #2 here. 1/n
Thrilled to post thread re: new single-cell lineage of mouse embryo reconstructed w/ DNA Typewriter. One animal, zygote to late organogenesis (E13.5). Tree has 1,340,794 transcriptionally profiled, annotated tips (cells), 1,142,588 dated internal nodes, rooted at zygote
1/n